<DOC>
	<DOCNO>NCT01206205</DOCNO>
	<brief_summary>The purpose Phase 2 study evaluate efficacy safety treatment bortezomib , lenalidomide dexamethasone patient untreated multiple myeloma . This study evaluate whether addition lenalidomide bortezomib dexamethasone increase Complete Response ( CR ) / good partial response ( VGPR ) rate High Dose Therapy ( HDT ) ASCT .</brief_summary>
	<brief_title>Frontline Therapy de Novo Multiple Myeloma Patients Under 65</brief_title>
	<detailed_description>Patients receive 3 induction cycle bortezomib , lenalidomide dexamethasone ( VRD ) follow high dose melphalan autologous stem cell transplantation . Two month haematological recovery , patient receive 2 consolidation cycle VRD maintenance therapy 1 year lenalidomide</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Patients diagnose multiple myeloma base standard diagnostic criterion new International Myeloma Foundation 2003 Diagnostic Criteria Subjects must symptomatic myeloma asymptomatic myeloma myelomarelated organ damage Subjects must measurable disease require systemic therapy . Male female subject 18 year age old Karnofsky Performance Status score ≥50 % ( Eastern Cooperative Oncology Group Performance Status score ≤2 ) Voluntary write informed consent must give performance studyrelated procedure part normal medical care , understand consent may withdraw subject time without prejudice future medical care . Women childbearing potential must negative serum urine pregnancy test within 3 day prior therapy . They must commit continued abstinence heterosexual intercourse begin 2 acceptable method birth control ( 1 highly effective method 1 additional effective method ) use time , begin least 4 week initiation Revlimid treatment . Women must also agree ongoing pregnancy test Men must agree father child agree use latex condom therapy 4 week last dose study drug , even successful vasectomy , partner childbearing potential . Subjects must treat previously systemic therapy multiple myeloma . Prior treatment corticosteroid radiation therapy disqualify subject ( maximum dose corticosteroid exceed equivalent 160 mg dexamethasone 2week period ) . Two week must elapse since date last radiotherapy treatment . Enrollment subject require concurrent radiotherapy ( must localize field size ) defer radiotherapy complete 2 week elapse since last date therapy . AL amylo ≥Grade 2 peripheral neuropathy clinical examination within 14 day enrollment Renal insufficiency ( serum creatinine &gt; 2.5 mg/dL ) Evidence mucosal internal bleeding and/or platelet refractory Platelet count &lt; 70,000 per µL ANC &lt; 1000 cells/mm3 AST ALT great equal 2 x ULN Total bilirubin &gt; 3 × ULN Myocardial infarction within 6 month prior enrollment accord NYHY Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormalities Clinically relevant active infection serious comorbid medical condition Prior malignancy except adequately treat basal cell squamous cell skin cancer , situ cervical , breast prostate cancer Female subject pregnant breastfeeding Serious medical psychiatric illness likely interfere participation study Uncontrolled diabetes mellitus Known HIV infection Known active hepatitis B C viral infection Known intolerance steroid therapy History allergy study medication , analogue , excipients various formulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>De novo Multiple Myeloma</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>induction therapy</keyword>
	<keyword>consolidation therapy</keyword>
	<keyword>maintenance therapy</keyword>
	<keyword>High dose therapy</keyword>
	<keyword>frontline therapy include new drug high dose therapy</keyword>
</DOC>